CandlesenseCandlesense
News/Companies/TENX

TENX News

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

TENX

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025, which is taking place from September 3-5, 2025, in New York, NY.

August 28, 2025Conference
Read more →

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

TENX

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts

August 6, 2025Clinical Trials
Read more →

Tenax Therapeutics Q1 EPS $(0.28) Misses $(0.19) Estimate

TENX

May 14, 2025
Read more →

Tenax Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.42) Estimate

TENX

March 25, 2025
Read more →

Tenax Therapeutics Announces $25M Private Placement With RTW Investments

TENX

March 5, 2025
Read more →

Tenax Therapeutics AnnounceS FDA Review Completion Of Updated Phase 3 Plan For TNX-103, Expands LEVEL Study Enrollment To 230 Patients With Over 95% Power; LEVEL-2 Global Study To Begin In 2025

TENX

March 5, 2025
Read more →